|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Co-Diagnostics, Inc. (CODX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
28,270,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Co-Diagnostics develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Co. may sell diagnostic equipment from other manufacturers as self-contained lab systems. Co. has a portable polymerase chain reaction (PCR) device that is designed to bring PCR to patients in point-of-care and even at-home settings. Co.'s diagnostics systems enable molecular testing for organisms and genetic diseases by automating procedures in both the development and administration of tests.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$5,697 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Durenard Eugene |
Director |
– • – |
2020-05-26 |
4 |
S |
$18.26 |
$456,500 |
D/D |
(25,000) |
0 |
|
- |
|
| Durenard Eugene |
Director |
– • – |
2020-05-20 |
4/A |
S |
$18.03 |
$450,750 |
D/D |
(25,000) |
25,000 |
|
- |
|
| Durenard Eugene |
Director |
– • – |
2020-05-20 |
4 |
S |
$18.40 |
$460,000 |
D/D |
(25,000) |
0 |
|
- |
|
| Durenard Eugene |
Director |
– • – |
2020-05-20 |
4 |
OE |
$0.71 |
$116,750 |
D/D |
50,000 |
25,000 |
|
- |
|
| Serbin Richard S |
Director |
– • – |
2020-05-19 |
4 |
S |
$18.50 |
$462,500 |
D/D |
(25,000) |
0 |
|
- |
|
| Serbin Richard S |
Director |
– • – |
2020-05-19 |
4 |
OE |
$0.71 |
$17,750 |
D/D |
25,000 |
25,000 |
|
- |
|
| Reagents, Llc |
Former 10% Owner |
– – – |
2020-04-01 |
4 |
D |
$192,505.00 |
$2,147,483,647 |
D/D |
(25,000) |
1,746,796 |
|
- |
|
| America 2030 Capital, Llc |
10% Owner |
– – • |
2018-12-06 |
4 |
D |
$0.01 |
$11,349 |
D/D |
(1,134,898) |
0 |
|
- |
|
| America 2030 Capital, Llc |
10% Owner |
– – • |
2018-07-18 |
4 |
D |
$0.01 |
$11,349 |
D/D |
(1,134,897) |
1,134,898 |
|
- |
|
| Satterfield Brent |
Chief Science Officer |
• • • |
2018-05-11 |
4 |
B |
$1.82 |
$2,375 |
D/D |
1,305 |
2,275,000 |
3.15 |
- |
|
| Satterfield Brent |
Chief Science Officer |
• • • |
2018-05-03 |
4 |
B |
$1.91 |
$955 |
D/D |
500 |
2,273,695 |
3.15 |
- |
|
| America 2030 Capital, Llc |
10% Owner |
– – • |
2018-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,269,795 |
|
- |
|
| Satterfield Brent |
Chief Science Officer |
• • • |
2018-04-23 |
4 |
B |
$2.02 |
$1,010 |
D/D |
500 |
2,273,198 |
3.15 |
- |
|
| Satterfield Brent |
Chief Science Officer |
• • • |
2018-04-16 |
4 |
B |
$1.94 |
$970 |
D/D |
500 |
2,272,698 |
3.15 |
- |
|
| Satterfield Brent |
Chief Science Officer |
• • • |
2018-04-09 |
4 |
B |
$4,920.00 |
$11,808,000 |
D/D |
2,400 |
2,272,198 |
3.23 |
- |
|
| Benson Reed L |
CFO and Secretary |
• – – |
2017-12-13 |
4 |
D |
$4.65 |
$95,641 |
I/I |
(20,568) |
0 |
|
- |
|
| Reagents, Llc |
Former 10% Owner |
– – – |
2017-09-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(181,817) |
1,771,796 |
|
- |
|
| Legends Capital Group, Llc |
|
– – • |
2017-07-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,300,344 |
|
- |
|
| Benson Reed L |
CFO and Secretary |
• – – |
2017-07-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
20,568 |
|
- |
|
| Satterfield Brent |
Chief Science Officer |
• • – |
2017-07-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,269,798 |
|
- |
|
95 Records found
|
|
Page 4 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
